Volume 18, Number 11—November 2012
Dispatch
Seroprevalence of Influenza A(H1N1)pdm09 Virus Antibody, England, 2010 and 2011
Katja Hoschler
, Catherine Thompson, Nick Andrews, Monica Galiano, Richard Pebody, Joanna Ellis, Elaine Stanford, Marc Baguelin, Elizabeth Miller, and Maria Zambon
, Catherine Thompson, Nick Andrews, Monica Galiano, Richard Pebody, Joanna Ellis, Elaine Stanford, Marc Baguelin, Elizabeth Miller, and Maria Zambon
Table 1
Seroprevalence of influenza A(H1N1)pdm09 virus antibody, England, 2010 and 2011*
| Characteristic |
No. seropositive samples/no. total samples† (% seropositive samples, 95% CI)
|
|||||||
|---|---|---|---|---|---|---|---|---|
|
Post–second wave‡
|
Pre–third
|
Post–third wave
|
||||||
| HI | MN | HI | MN | HI | MN | |||
| Age group, y | ||||||||
|
<5 |
36/98 (0.37, 0.27–0.47) | 31/77 (0.4, 0.29–0.52) | 94/182 (0.52, 0.44–0.59) | 88/174 (0.51, 0.43–0.58) | 99/160 (0.62, 0.54–0.69) | 93/150 (0.62, 0.54–0.7) | ||
|
5–14 |
132/213 (0.62, 0.55–0.69) | 69/107 (0.64, 0.55–0.73) | 142/244 (0.58, 0.52–0.64) | 152/237 (0.64, 0.58–0.7) | 155/200 (0.78, 0.71–0.83) | 146/199 (0.73, 0.67–0.79) | ||
|
15–24 |
68/154 (0.44, 0.36–0.52) | 44/101 (0.44, 0.34–0.54) | 152/405 (0.38, 0.33–0.42) | 156/400 (0.39, 0.34–0.44) | 216/320 (0.68, 0.62–0.73) | 188/311 (0.6, 0.55–0.66) | ||
|
25–44 |
66/200 (0.33, 0.27–0.4) | 31/83 (0.37, 0.27–0.49) | 106/370 (0.29, 0.24–0.34) | 114/370 (0.31, 0.26–0.36) | 187/294 (0.64, 0.58–0.69) | 155/283 (0.55, 0.49–0.61) | ||
|
45–64 |
59/220 0.27, 0.21–0.33) | 42/110 (0.38, 0.29–0.48) | 69/320 (0.22, 0.17–0.26) | 93/318 (0.29, 0.24–0.35) | 62/138 (0.45, 0.36–0.54) | 52/135 (0.39, 0.3–0.47) | ||
|
65–74 |
36/145 (0.25, 0.18–0.33) | 27/87 (0.31, 0.22–0.42) | 35/168 (0.21, 0.15–0.28) | 42/167 (0.25, 0.19–0.32) | 38/74 (0.51, 0.39–0.63) | 38/74 (0.51, 0.39–0.63) | ||
|
>75 |
55/172 (0.32, 0.25–0.4) | 77/163 (0.47, 0.39–0.55) | 16/93 (0.17, 0.1–0.26) | 25/92 (0.27, 0.18–0.37) | 46/71 (0.65, 0.53–0.76) | 39/71 (0.55, 0.43–0.67) | ||
| Region§ | ||||||||
|
Total |
1,202 | 1,782 | 1,257 | |||||
|
North West |
561 | 624 | 337 | |||||
|
South West |
404 | 232 | 265 | |||||
|
North East |
237 | 526 | 179 | |||||
|
East |
0 | 292 | 122 | |||||
|
Yorkshire and Humber |
0 | 108 | 354 | |||||
*HI, hemagglutination inhibition assay; MN, microneutralization assay.
†Samples with titers >32 by HI or >40 by MN,
‡For data consistency, samples from only North West, South West, and North East regions were included in this analysis because these regions also were among the 5 regions in pre– and post–third wave samples.
§Numbers by region describe total available number of samples (all analyzed at least by HI assay).
Page created: October 05, 2012
Page updated: October 05, 2012
Page reviewed: October 05, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.